Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America
Authors:
- Marta Pineda-MoncusíMPMarta Pineda-Moncusí
- Alexandros RekkasARAlexandros Rekkas
- Álvaro Martínez PérezÁPÁlvaro Martínez Pérez
- Angela LeisALAngela Leis
- Carlos Lopez GomezCGCarlos Lopez Gomez
- Eric FeyEFEric Fey
- Erwin BruninxEBErwin Bruninx
- Filip MaljkovićFMFilip Maljković
- Francisco Sánchez-SáezFSFrancisco Sánchez-Sáez
- Jordi RodeiroJRJordi Rodeiro
- Loretta Zsuzsa KissLKLoretta Zsuzsa Kiss
- Michael FranzMFMichael Franz
Preprint
Abstract
Importance Drug production not meeting the demand leaves affected patients in a vulnerable position. Objective To describe incidence and prevalence of medicines with suggested shortages in at least one European country Design We performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Setting Setting included primary care, secondary care, and various disease registries whose previously collected data was leveraged. Participants We included all patients with at least 365 days of history on the database. Exposures We investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39). Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage. Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries. Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.Keywords
This publication has 27 references indexed in Scilit:
- Drug Shortages Prior to and During the COVID-19 PandemicJAMA Network Open, 2024
- Tackling medicine shortages during and after the COVID-19 pandemic: Compilation of governmental policy measures and developments in 38 countriesHealth Policy, 2024
- OHDSI Standardized Vocabularies—a large-scale centralized reference ontology for international data harmonizationJournal of the American Medical Informatics Association, 2024
- Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profileThe Lancet, 2023
- Drug shortages. Part 1. Definitions and harmsBritish Journal of Clinical Pharmacology, 2023
- Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemicThe Lancet Respiratory Medicine, 2023
- Increased rates of secondary bacterial infections, including Enterococcus bacteremia, in patients hospitalized with coronavirus disease 2019 (COVID-19)Infection Control & Hospital Epidemiology, 2021
- Drug shortage management: A qualitative assessment of a collaborative approachPLOS ONE, 2021
- Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usageClinical Microbiology and Infection, 2020
- The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical CentersClinical Infectious Diseases, 2017